PIK3CA genotype and treatment decisions in human epidermal growth factor receptor 2-positive breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 12, 2015, Pages 1318-1321

  Cescon, David W ^a   Bedard, Philippe L ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; DISEASE FREE SURVIVAL; DNA ISOLATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENZYME SUBUNIT; EVENT FREE SURVIVAL; GENOTYPE; HUMAN; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MUTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMATIC MUTATION; TREATMENT OUTCOME; BREAST NEOPLASMS; FEMALE; GENETICS; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2;

EID: 84929430275     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.3160     Document Type: Editorial

References (36)

1. Wagle N, Berger MF, Davis MJ, et al: High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2:82-93, 2012
2. Bedard P, Oza A, Tsao M, et al: Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). J Clin Oncol 31:656s, 2013 (suppl 15s; abstr 11002)
3. Hollebecque A, Massard C, De Baere T, et al: Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial - Interim results. J Clin Oncol 31:144s, 2013 (suppl 15s; abstr 2512)
4. Abramson VG, Cooper Lloyd C, Ballinger T, et al: Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res Treat 145:389-399, 2014
5. Pogue-Geile KL, Song N, Jeong J-H, et al: Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in NSABP B-31 trial. J Clin Oncol 33:1340-1347, 2015
6. Majewski IJ, Nuciforo P, Mittempergher L, et al: PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 33:1334-1339, 2015
7. Lawrence MS, Stojanov P, Mermel CH, et al: Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501, 2014
8. Loi S, Michiels S, Lambrechts D, et al: Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 105:960-967, 2013
9. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007
10. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
11. Kataoka Y, Mukohara T, Shimada H, et al: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21:255-262, 2010
12. Eichhorn PJ, Gili M, Scaltriti M, et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230, 2008
13. Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647-1656, 2010
14. Razis E, Bobos M, Kotoula V, et al: Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128:447-456, 2011
15. Cizkova M, Dujaric M, Lehmann-Che J, et al: Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 108:1807-1809, 2013
16. Jensen J, Knoop A, Laenkholm AV, et al: PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23:2034-2042, 2012
17. Baselga J, Cortés J, Im SA, et al: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32:3753-3761, 2014
18. Krop IE, LoRusso P, Miller KD, et al: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241, 2012
19. Miller KD, Diéras V, Harbeck N, et al: Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 32:1437-1444, 2014
20. Baselga J, Verma S, Ro J: Relationship between tumour biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). Cancer Res 73, 2013 (abstr LB-63)
21. Kim SB, Wildiers H, Krop I, et al: Relationship between tumor biomarkers and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib. J Clin Oncol 32:31s, 2014 (suppl 15s; abstr 605)
22. Xu B, Guan Z, Shen Z, et al: Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2 positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. Breast Cancer Res 16:405, 2014
23. Schneeweiss A, Chia S, Hegg R, et al: Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumabbased therapy: An exploratory analysis of the TRYPHAENA study. Breast Cancer Res 16:R73, 2014
24. Gianni L, Bianchini G, Kiermaier A, et al: Neoadjuvant pertuzumab and trastuzumab: Biomarker analyses of a 4-arm randomized phase II study (Neo-Sphere) in patients with HER2-positive breast cancer. Cancer Res 71, 2011 (abstr S5-1)
25. Guarneri V, Dieci MV, Carbognin L, et al: Activity of neoadjuvant lapatinib plus trastuzumab for early breast cancer according to PIK3CA mutations: Pathological complete response (pCR) rate in the CherLOB study and pooled analysis of randomized trials. Ann Oncol 25, 2014 (abstr 2540)
26. Loibl S, von Minckwitz G, Schneeweiss A, et al: PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 32:3212-3220, 2014
27. Barok M, Isola J, Pályi-Krekk Z, et al: Trastuzumab causes antibody-dependent cellular cytotoxicity: Mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6:2065-2072, 2007
28. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al: First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-> L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 32:4s, 2014 (suppl 15s; abstr LBA4)
29. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014
30. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007
31. Ogston KN, Miller ID, Payne S, et al: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 12:320-327, 2003
32. Swain S, Kim S, Cortes J, et al: Final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. Presented at the European Society of Medical Oncology Congress, Madrid, Spain, September 26-30, 2014
33. Henry NL, Schott AF, Hayes DF: Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: Clinical validity but not utility. J Clin Oncol 32:3207-3209, 2014
34. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
35. Garrett JT, Sutton CR, Kurupi R, et al: Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res 73:6013-6023, 2013
36. Brachmann SM, Hofmann I, Schnell C, et al: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106:22299-22304, 2009